Vaborbactam | CAS#1360457-46-0 | beta-Lactamase Inhibitor

MedKoo Cat#: 558276 | Name: Vaborbactam

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vaborbactam, also known as RPX7009, is a potent and selective beta-lactamase inhibitor. Vaborbactam shows broad-spectrum inhibitor, notably restoring the activity of carbapenems against KPC-producing strains. Combined with a carbapenem, Vaborbactam is a promising product for the treatment of multidrug resistant Gram-negative bacteria. For recent consecutive strains of Bacteroides species, the MIC(90) for biapenem-RPX7009 was 1 μg/ml, with a MIC(90) of 4 μg/ml for meropenem.

Chemical Structure

Vaborbactam

CAS#1360457-46-0

Theoretical Analysis

MedKoo Cat#: 558276

Name: Vaborbactam

CAS#: 1360457-46-0

Chemical Formula: C12H16BNO5S

Exact Mass: 297.0842

Molecular Weight: 297.13

Elemental Analysis: C, 48.51; H, 5.43; B, 3.64; N, 4.71; O, 26.92; S, 10.79

Price and Availability

Size	Price	Availability
5mg	USD 750.00	2 Weeks
10mg	USD 1,350.00	2 Weeks
50mg	USD 3,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

RPX-7009; RPX7009; RPX 7009; MP-7009; MP7009; MP 7009; REBO-07; REBO07; REBO 07; MP-7; MP 7; MP7; Vaborbactam; Vabomere.

IUPAC/Chemical Name

2-((3R,6S)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic acid

InChi Key

IOOWNWLVCOUUEX-WPRPVWTQSA-N

InChi Code

InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1

SMILES Code

O=C(O)C[C@@H]1CC[C@H](NC(CC2=CC=CS2)=O)B(O)O1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 297.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gibson B. A Brief Review of a New Antibiotic: Meropenem-vaborbactam. Sr Care Pharm. 2019 Mar 1;34(3):187-191. Review. PubMed PMID: 31155025. 2: Albin OR, Patel TS, Kaye KS. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections. Expert Rev Anti Infect Ther. 2018 Dec;16(12):865-876. doi: 10.1080/14787210.2018.1542300. Epub 2018 Nov 5. Review. PubMed PMID: 30372359. 3: Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae. Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Review. PubMed PMID: 30254477; PubMed Central PMCID: PMC6140735. 4: Wu G, Cheon E. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis. Expert Opin Pharmacother. 2018 Sep;19(13):1495-1502. doi: 10.1080/14656566.2018.1512586. Epub 2018 Aug 30. Review. PubMed PMID: 30160990. 5: Dhillon S. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs. 2018 Aug;78(12):1259-1270. doi: 10.1007/s40265-018-0966-7. Review. Erratum in: Drugs. 2018 Sep;78(13):1383. PubMed PMID: 30128699; PubMed Central PMCID: PMC6132495. 6: Burgos RM, Biagi MJ, Rodvold KA, Danziger LH. Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. Expert Opin Drug Metab Toxicol. 2018 Oct;14(10):1007-1021. doi: 10.1080/17425255.2018.1511702. Epub 2018 Sep 19. Review. PubMed PMID: 30106599. 7: Lee YR, Baker NT. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. Epub 2018 Apr 19. Review. PubMed PMID: 29675787. 8: Cho JC, Zmarlicka MT, Shaeer KM, Pardo J. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination. Ann Pharmacother. 2018 Aug;52(8):769-779. doi: 10.1177/1060028018763288. Epub 2018 Mar 7. Review. PubMed PMID: 29514462. 9: Jorgensen SCJ, Rybak MJ. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae. Pharmacotherapy. 2018 Apr;38(4):444-461. doi: 10.1002/phar.2092. Epub 2018 Mar 28. Review. PubMed PMID: 29427523. 10: McCarthy MW, Walsh TJ. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections. Drugs Today (Barc). 2017 Oct;53(10):521-530. doi: 10.1358/dot.2017.53.10.2721815. Review. PubMed PMID: 29286054. 11: Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs. 2018 Jan;78(1):65-98. doi: 10.1007/s40265-017-0851-9. Review. Erratum in: Drugs. 2018 May 10;:. PubMed PMID: 29230684.